C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

Gross Margin
C4X Discovery Holdings PLC

99.9%
Current
84%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
99.9%
=
Gross Profit
24.7m
/
Revenue
24.7m

Gross Margin Across Competitors

Country UK
Market Cap 30.3m GBP
Gross Margin
100%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 201.7B USD
Gross Margin
41%
Country US
Market Cap 173.6B USD
Gross Margin
60%
Country KR
Market Cap 67.8T KRW
Gross Margin
49%
Country CH
Market Cap 38.6B CHF
Gross Margin
29%
Country US
Market Cap 39.6B USD
Gross Margin
55%
Country US
Market Cap 36.8B USD
Gross Margin
35%
Country US
Market Cap 26.9B USD
Gross Margin
59%
Country US
Market Cap 23.5B USD
Gross Margin
35%
Country US
Market Cap 23.2B USD
Gross Margin
60%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.26 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
99.9%
=
Gross Profit
24.7m
/
Revenue
24.7m
What is the Gross Margin of C4X Discovery Holdings PLC?

Based on C4X Discovery Holdings PLC's most recent financial statements, the company has Gross Margin of 99.9%.